格隆汇11月19日丨星太链集团(00399.HK)公布，董事会会议将于2025年11月28日星期五举行，以考虑及 批准(其中包括)公司及其附属公司截至2025年9月30日止六个月之综合中期业绩。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部分內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 STARCOIN GROUP LIMITED 星太鏈集團有限公司 （前稱領航醫藥及生物科技有限公司） （於開曼群島註冊成立並於百慕達存續之有限公司） （股份代號：399） 董事會會議通告 請同時參閱本公告於本公司網站 w w w .starcoingroup.com 及 www.irasia.com/listco/hk/ starcoingroup 刊 載之內容。 星太鏈集團有限公司（「本公司」）董事會（「董事會」）謹此公佈，董事 會會議將於二零二五年十一月二十八日星期五舉行，以考慮及批准（其中包 括）本公司及其附屬公司截至二零二五年九月三十日止六個月之綜合中期業 績。 承董事會命 星太鏈集團有限公司 主席 仰融 香港，二零二五年十一月十九日 於本公告日期，董事會包括仰融博士（主席兼執行董事）、高源興先生（執行董事）、唐榕先生 （執行董事）、齊淑娟女士（執行董事）、龍凡博士（執行董事）、伍鳴博士（執行 ...

智通财经APP获悉，截止11月17日收盘，有45只股票创52周新高，其中中生北控生物科技(08247)、豆盟 科技(01917)、世纪联合控股(01959)创高率位于前3位，分别为55.17%、48.72%、33.70%。 52周新低排行 | 股票名称 | 收盘价 | 最低价 | 创低率 | | --- | --- | --- | --- | | 星太链集团(00399) | 0.064 | 0.059 | -59.31% | | 星空华文(06698) | 1.230 | 1.000 | -13.79% | | 力盟科技(02405) | 1.040 | 0.900 | -13.46% | | 山高控股(00412) | 1.760 | 1.550 | -12.43% | | 大行科工(02543) | 40.300 | 39.800 | -9.13% | | 澳门励骏(01680) | 0.310 | 0.275 | -8.33% | | ＸＬ二南策略－Ｕ | 2.534 | 2.444 | -8.05% | | (09799) | | | | | IFBH(06603) | 19.370 | 19.30 ...

整体看，市场处于消化压力、寻找新平衡的阶段。资金在高股息防御品种、区域性政策主题和超跌的科技龙头之间进行再配置。 11月17日，A股震荡调整，沪指跌0.43%，深成指跌0.35%，创业板跌0.8%。福建本地股、军工、锂矿、AI应用等板块领涨；贵金属、医药、光伏 设备、培育钻石等板块领跌。 具体来看，福建本地股持续走强，三木集团、平潭发展等近20股涨停，资金对区域经济主题的追捧正进入白热化阶段。 锂电板块反复活跃，盛新锂能、融捷股份等封板，延续了上周的强势。尽管龙头宁德时代因股东减持低开，但板块整体依然强势，消息面上，锂 电材料涨价潮持续传导，氯化亚砜迎来价格猛涨。 军工股盘中拉升，长城军工、航天发展等涨停。消息面上，外交部、文旅部、教育部等多部门重要提醒，近期避免前往日本，日本公然发表挑衅 言论，严重恶化中日人员交流氛围。中泰证券表示，日方挑衅使得地缘局势不确定性加剧，可能成为"推动祖国统一"的一大隐患，在我国核心利 益受到外部威胁的情况下，国防建设投入有望持续加大，规划目标有望加速实现，将推动我国军工产业进一步高质量发展。 AI应用概念走强，三六零、宣亚国际等多股涨停。在经历调整后，资金再度回流至具备想象空 ...

Core Viewpoint - Starcoin Group Limited (formerly known as Innovative Pharmaceutical Biotech Limited) experienced a significant stock price drop, with a decline exceeding 70% following a notification from the Hong Kong Stock Exchange regarding insufficient operational levels and asset value to support continued listing [1][2]. Group 1: Company Announcement and Stock Performance - On November 14, 2025, the company received a letter from the Stock Exchange indicating that it failed to maintain sufficient operational levels and asset value, leading to a decision to suspend trading of its shares on November 26, 2025 [2][3]. - The company had previously announced a failed placement agreement to issue up to 145 million shares at HKD 0.415 per share, as the conditions precedent were not met by September 11, 2025 [1][3]. Group 2: Financial Performance - For the fiscal year ending March 31, 2025, the company reported a revenue of HKD 2.091 million, a year-on-year decrease of 68.28%, and a net loss attributable to shareholders of HKD 346 million, compared to a profit of HKD 103 million in the previous year [5]. - The basic earnings per share for the reporting period were -HKD 0.2001, with net cash flow from operating activities at -HKD 10.555 million, a decrease of HKD 2.276 million year-on-year [5].

Core Viewpoint - Starcoin Group Limited (formerly known as Innovative Pharmaceutical Biotech Limited) experienced a significant stock crash, with a drop exceeding 70% due to regulatory actions from the Hong Kong Stock Exchange regarding its operational viability and asset value [2][5][9]. Company Announcement - On November 14, 2025, Starcoin Group received a notification from the Hong Kong Stock Exchange stating that it failed to maintain sufficient operational levels and asset value, leading to a suspension of its shares on November 26, 2025, unless a review is requested [4][6]. - The company announced that a planned share placement of up to 145 million shares at HKD 0.415 per share has become void due to unmet conditions by September 11, 2025, terminating all responsibilities between the placement agent and the company [2][7]. Financial Performance - For the fiscal year ending March 31, 2025, Starcoin Group reported a revenue of HKD 2.091 million, a decline of 68.28% year-on-year, and a net loss attributable to shareholders of HKD 346 million, compared to a profit of HKD 103 million in the previous year [10]. - The basic earnings per share for the reporting period was -HKD 0.2001, with a net cash outflow from operating activities of HKD 10.555 million, a decrease of HKD 2.276 million year-on-year [10]. Company Background - Starcoin Group operates in the pharmaceutical and biotechnology sector, with five divisions including genetic testing services, bioproduct distribution, beauty equipment trade, securities investment, and research on oral insulin products [9]. - The company had previously seen a significant stock price increase of nearly 100% during June to July 2025 before entering a downward trend [9].

Core Viewpoint - Star Chain Group (00399.HK) experienced a significant decline in its stock price, dropping over 70% in early trading, with a current decrease of 66.81%, trading at 0.079 HKD, and a transaction volume of 7.6626 million HKD [1] Company Summary - Star Chain Group's stock price fell by more than 70% in early trading [1] - As of the latest update, the stock is down 66.81% [1] - The current trading price is 0.079 HKD [1] - The total transaction volume reached 7.6626 million HKD [1]

Core Viewpoint - Xing Tai Chain Group (00399) experienced a significant decline in stock price, dropping over 70% in early trading, with a current price of 0.079 HKD and a trading volume of 7.6626 million HKD [1] Group 1: Stock Performance - The company's stock fell by 66.81% as of the latest report [1] - The trading volume reached 7.6626 million HKD, indicating heightened market activity [1] Group 2: Regulatory Announcement - The company received a letter from the Stock Exchange on November 14, 2025, stating that it failed to maintain sufficient operational levels and asset value to support continued listing [1] - According to Listing Rule 6.01(3), trading of the company's shares will be suspended on November 26, 2025, unless the company applies for a review of this decision [1] - The board of directors has decided to request a review of the decision and is preparing the necessary documentation [1] Group 3: Investor Advisory - The company has informed shareholders and potential investors about its decision to seek a review of the suspension [1] - The outcome of the review by the Listing Committee remains uncertain [1]

经审阅该决定函件，公司董事会已决定要求将该决定提交上市委员会复核，并正在编制相关要求函件。 谨此提醒股东及潜在投资者，公司已决定要求复核该决定，惟上市委员会对有关复核的结果并不明朗。 智通财经APP获悉，星太链集团(00399)早盘跌超70%，截至发稿，跌66.81%，报0.079港元，成交额 766.26万港元。 消息面上，星太链集团今早公告，于2025年11月14日，公司接获联交所的函件，通知公司其作出的决 定，即经考虑联交所可得资料(包括公司的提呈文件)，根据第13.24条的规定，公司未能维持足够的运营 水平和足够价值的资产支持其运营，令其股份得以继续上市，并将根据上市规则第6.01(3)条，于2025年 11月26日暂停公司股份买卖，除非公司根据其在第2B章项下的权利申请复核该决定。 ...

Core Viewpoint - The stock of Star Chain Group experienced a significant drop of over 60% upon opening on November 17, 2025, due to a decision from the Hong Kong Stock Exchange regarding insufficient operational levels and asset value [1] Group 1 - The company received a notice from the Stock Exchange on November 14, 2025, indicating that trading of its shares will be suspended on November 26, 2025 [1] - The board of directors has decided to request a review of this decision by the Listing Committee and is preparing the necessary documentation [1]